Leadership at NuvOx Pharma

Executive Team

Evan Unger, MD

Co-Founder, Chief Executive Officer, and President

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on over 118 issued US patents. He is a board-certified radiologist and was previously a Professor of Radiology and Biomedical Engineering at the University of Arizona.

Betty R Weaver, CPA

Chief Financial Officer

Ms. Weaver has over 18 years in public accounting with a regional firm in the Dallas/Fort Worth area and has principal accounting firms in Texas and Arizona. Ms. Weaver is a financial expert in providing early and expansion stage companies in Biotech and Life Sciences with planning, analysis and full CFO services. She also has over 15 years in industry with responsibility for operations, accounting, treasury, facilities, human resources and information technology. Ms. Weaver completed her BS degree in Accounting/Information Systems at University of North Texas. She holds CPA licenses in Texas and Arizona.

John McGonigle, BSME, MBA

Director of Business Development

John has a diverse background in engineering and entrepreneurship and has been with NuvOx since 2014. His roles at NuvOx have included business development, statistics, and scientific and strategic analyses. Prior to NuvOx, he worked with a small biotechnology company, Instant Bioscan, in a variety of business an engineering roles that supported its acquisition by Mettler Toledo. He led due diligence on several biotech companies seeking investment for the Desert Angels.

Board of Directors

Evan Unger, MD

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on over 118 issued US patents. He is a board-certified radiologist and was previously a Professor of Radiology and Biomedical Engineering at the University of Arizona.

Marvin J Slepian, MD

Marvin J. Slepian, M.D. is Professor of Medicine (Cardiology), Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his Internal Medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He completed his Cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a second fellowship in Interventional Cardiology at Cleveland Clinic. Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian has founded numerous medical device companies, including Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax and Hansen Medical, and has served as acting CEO and Board Member of several medical device startups. He earned his A.B. in Biochemical Sciences and Science in Human Affairs from Princeton University, and his M.D. from the University of Cincinnati College of Medicine. He has received additional post-doctoral training at MIT and Washington University.

Richard Carmona MD, MPH, FACS

Richard Carmona MD, MPH, FACS was the 17th Surgeon General of the United States and is the Distinguished Professor of Public Health at the Mel and Enid Zuckerman College of Public Health. He also holds faculty appointments as a Professor of Surgery and Pharmacy. Trained in general and vascular surgery, Dr. Carmona also completed a National Institutes of Health-sponsored fellowship in trauma, burns, and critical care. Dr. Carmona was then recruited jointly by the Tucson Medical Center and the University of Arizona to start and direct Arizona's first regional trauma care system. He went on to become the chairman of the State of Arizona Southern Regional Emergency Medical System, a professor of surgery, public health and family and community medicine at the University of Arizona, and the Pima County Sheriff's Department surgeon and deputy sheriff. He is also a Fellow of the American College of Surgeons. Dr. Carmona's interest in public health stemmed from the realization that most of his patients' illnesses and injuries were completely preventable. In 2002 Dr. Carmona was nominated by the president and unanimously confirmed by the United States Senate to become the 17th Surgeon General of the United States. Dr. Carmona was selected because of his extensive experience in public health, clinical sciences, health care management, preparedness, and his commitment to prevention as an effective means to improve public health and reduce health care costs while improving the quality and quantity of life. As Surgeon General, Dr. Carmona focused on prevention, preparedness, health disparities, health literacy, and global health to include health diplomacy. He also issued many landmark Surgeon General Communications during his tenure, including the definitive Surgeon General's Report about the dangers of second-hand smoke.

Jonathan T. Schilling

Jonathan is retired from a 30-year career in the sale and marketing of employee benefit medical/dental plans for Blue Cross and Delta Dental. He received a BS in Information Science Management from the University of San Francisco. He is an active investor and recently invested in NuvOx and led a portion of the round totaling $1.6 Million from a group of investors. His previous investments have included Schilling Robotics (President, Tyler Schilling, Jonathan's brother), which sold in 2012 at a total valuation of several hundred million dollars. The result was an ROI of 22x for the Unit A investors. Jonathan has known Evan Unger since 1969 (high school) and now resides in San Francisco.